We would love to hear your thoughts about our site and services, please take our survey here.
I was also getting a slightly higher quote to sell for all my holdings than the offer price as well occasionally as per the bid offer spread I could see on Halifax.
The spouse cannot be expected to know any insider information from the Director, so are free to trade as often and as much as they wish in my view. Perhaps the Director of Communication may not even be privy to this information. I don't think the Company can hold off issuing any material news of the trial to Shareholders just because the spouse of a director wanted to do a small trade. But agree this is eyebrow raising when there is so much expectation built-in for the results to drop in any time.
I am struggling to get my head around the numbers as well and figure out what this is now going to be valued at. Hopefully we will get some analyst reports to indicate what sort of rerate are we looking at. Definitely I am not going to sell this early until it does a few bag multiples this year. The story seems to have only just started it seems.
This is an article from September, but gives a good indicator of recent M&A activity.
https://www.nature.com/articles/d43747-021-00107-w
If we were to be sold at just £2bn if we manage to achieve a successful phase 3 trial I would honestly be disappointed, especially considering the large potential we actually have even beyond just being a treatment for Covid.
For me the £50- £75 valuation is not completely unrealistic if we manage to achieve phase 3 success and actually commercialise with about £1bn of annual sales.
Of course everything hinges on the phase 3 results otherwise we are back to being valued in tens of pences.
Another very interesting comment from from Sir Stephen;
“For example, if a bat is infected by a SARS-type coronavirus, the virus has evolved very sophisticated ways of avoiding the interferon beta pathway. However, bats have a very high baseline production of interferon, that overwhelm the virus so that the bat can tolerate the virus without disease. But as soon as the coronavirus gets into humans, where there isn’t a high level of baseline interferon production, things get problematic with rapid spread of the virus leading to COVID-19. So, here was a green light going for us to say, ‘look, we have a drug that could actually replace what’s missing...’”
I really just hope we can just get the trial results out soon. Not sure about others but just want to get it over with this rather than spend a few more nervous and sleepless nights with results due any day. Thinking it might help me I sold half my holding this morning to reduce my exposure, but then was again doubting myself since then as to why I did this after having held for so many months. I went back read the phase 2 trial Lancet report, all the RNS updates, the home trial subset result, and our primary and secondary endpoint objectives targeted for phase 3 and thought did I just take a very hasty decision when the odds are so favourable for success. To be honest this is my biggest exposure but not so large to cause me any material discomfort. And now this tweet has just popped in. Have just bought everything back I sold albeit a small profit. Hopefully I will sleep better tonight.
Seems like Kight still has orders to fill in using any sells that come in. Can't buy anything for the past 2 days, going straight to NT.
The guy has pumped in a £1.5 million for his holding so definitely not small change.
A very good positive surprise indeed on the rigs and bodes well for 2022. Glad I got my top-up at the right time under 10p.
What I found odd was the voting figures. On the stock options resolution only 130k shares voted against. How is that possible when a number of posters have mentioned they have voted against, surely that has got to be over 130k shares or do our brokers not do what they were supposed to pass on.
Very interesting that they deleted so quickly. Was it in response to this comment in the article "A nasal swab to measure the immune response in newly infected adults could be used to identify those at higher risk who may be candidates for pre-emptive monoclonal antibody treatment.
While other research indicates inhalation of interferons could be a viable therapy."
Seems like SNG want to keep low profile ahead of the readouts.
Is there any link for the resolutions on the Company website. I couldn't find any link. Don't usually bother with voting but will vote against this time. Chatted with an online agent for my broker and they can submit my votes on my behalf.
What's happening here? Now down to below 5p. Anyone with any information on what the share price performance target is for the Management?
This share has been nothing but a ****show so far for me. Will take a good 70% rise from here just for me to break even and worry if I will ever see that day. Looks like I will have to forget this one for the next couple of years.
Superb news to wake up to. It will be an interesting few weeks coming up. If we are to achieve a few multiples of where the current SP is on a successful trial, expect a re
rating to start fairly soon in anticipation of this, as the gap will be too large to suddenly jump to otherwise in early 2022. It will also be interesting to see what Polygon will be up to next.